{"url_path":"/sec/aeon/8-k/2026-05-14/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statement and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1837607/0001837607-26-000043-index.html","accession_number":"0001837607-26-000043","cik":"0001837607","ticker":"AEON","issuer_name":"AEON Biopharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1837607/0001837607-26-000043-index.html","primary_entity_key":"0001837607","primary_entity_name":"AEON Biopharma, Inc."},"word_count":99,"has_tables":true,"body_markdown":"**Item 9.01. Financial Statement and Exhibits.**\n\n​\n\n(d) Exhibits.\n\n​\n\n​\n\n**Exhibit No.**\n\n**Description**\n\n​\n\n​\n\n​\n\n99.1\n\n[Corporate Presentation, dated May 2026](aeon-20260514xex99.htm)\n\n104\n\n​\n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n​\n\n​\n\n​\n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n​\n\n​\n\n​\n\n​\n\n​\n\n**AEON Biopharma, Inc.**\n\nDate: May 14, 2026\n\nBy:\n\n/s/ Robert Bancroft\n\n​\n\n​\n\nRobert Bancroft\n\n​\n\n​\n\nChief Executive Officer\n\n​\n\n​\n\n​\n\n​"}